Medicover Genetics publishes insights on advances in non-invasive prenatal testing

Medicover Genetics Editorial Team|

Scientifically checkedView our editorial guidelines
Scientifically checked

Medicover Genetics is pleased to announce the publication of an article by PD Markus Stumm in highlighting advances in screening for genetic abnormalities with non-invasive prenatal testing (NIPT).

In the article, Dr. Stumm explains how NIPT uses fetal cell-free DNA (cfDNA) extracted from a maternal blood sample to screen for potential chromosomal abnormalities, including trisomy 13 (Patau syndrome), 18 (Edwards syndrome), and 21 (Down syndrome).

A key focus of the article is the use of target capture sequences (TACS), long synthetic DNA probes designed by Medicover Genetics Cyprus, to analyse the cfDNA. TACS target specific genome regions of interest and avoid unnecessary regions, improving the precision and accuracy of the test. The article continues with a valuable discussion for clinicians about the importance of fetal fraction—the proportion of cfDNA in the maternal bloodstream—for ensuring accurate results in NIPT.

Dr. Stumm concludes the article by noting, “With further technological advances and responsible innovation, NIPT remain a screening avenue for the detection of additional genetic conditions.”

Read the full article .

Last updated: June 8, 2026

Latest articles

All about genetics
Health and well-being
Hereditary diseases

  • VERACITY

    New-generation non-invasive prenatal screening from week 9 of pregnancy, analysing fetal cell-free DNA in maternal blood to detect selected chromosomal abnormalities with high sensitivity and specificity for early and reliable prenatal risk assessment.

  • Pharmacogenomics

    Enabling personalised treatments for safer, more effective care through genetic insights that guide optimal prescribing from the start and refine therapy when patients experience side effects or poor response.

  • ebiom+

    A comprehensive assessment of the endometrial microbiome and chronic endometritis pathogens to enhance clinical outcomes, prevent treatment delays, and support a more informed, personalised fertility care.

  • WES

    Advanced sequencing that simultaneously analyses a broad range of genes to detect the genetic basis of complex diseases, improve diagnostic accuracy, and inform recurrence risk assessment for better clinical decision-making.

Why Medicover Genetics

Leader in genetic testing with >25 years of experience in counselling and diagnostics

Comprehensive CE-IVD kit portfolio and seamless Technology Transfer solution for laboratories of any size

End-to-end clinical workflow from sample processing to sequencing analysis and reporting

CAP- and CLIA- and ISO15189 accredited, GMP- and ISO9001 and 13485 certified

Are you a patient?

Are you a physician?